You are here: Home: Audio Program Guide: CCU Think Tank 2008: CCU Think Tank 2008 Audio
 
 

  Faculty Panel Discussion


  
Track 1 Reliability of K-ras mutation assessment
audio
Track 2 Evaluation of K-ras mutation status in clinical practice
Track 3 Case discussion: A 64-year-old man with K-ras mutant, metastatic colon cancer previously treated with FOLFOX and FOLFIRI/bevacizumab
Track 4 Treatment options for patients with progressive, K-ras mutant colon cancer resistant to standard therapies
Track 5 Best supportive care versus EGFR inhibitors for patients with K-ras mutant colon cancer who have exhausted evidence-based treatment options
Track 6 CALGB-C80405: A Phase III randomized study of front-line cetuximab and/or bevacizumab in combination with FOLFOX or FOLFIRI
Track 7 Correlation between the IgE antibody and anaphylactic reactions to cetuximab
Track 8 Molecular predictors of response to systemic therapy
Track 9 Development of a multigene assay to assess risk of recurrence in colorectal cancer
Track 10 Role and clinical implications of K-ras mutation in tumorigenesis
Track 11 First BEAT: An international first-line bevacizumab expanded access trial in advanced colorectal cancer
Track 12 Cardiovascular considerations for patients treated with bevacizumab
audio
Track 13 Hypertension as a predictor of response to bevacizumab
audio
Track 14 Case discussion: A 50-year-old woman reluctant to stop therapy after receiving three years of treatment with chemotherapy/bevacizumab for metastatic rectal cancer
audio
Track 15 Impact of continuing bevacizumab beyond disease progression
audio
Track 16 Potential risks of long-term bevacizumab
Track 17 Continuous active therapy versus treatment holidays for patients with advanced disease
Track 18 Prognostic implications of calcified metastases
Track 19 Rationale for and clinical investigations of continuing bevacizumab beyond disease progression
Track 20 Inhibition of VEGF receptors in patients with disease progression on bevacizumab
Track 21 Research value and limitations of registry trials
Track 22 Phase II randomized trial of FOLFOX/cediranib versus FOLFOX/bevacizumab in previously treated metastatic colorectal cancer
Track 23 Challenges in the development of biologic agents
Track 24 Antitumor activity of tyrosine kinase inhibitors and potential long-term risks
Track 25 Mechanisms of action of bevacizumab
Track 26 Case discussion: A 38-year-old man with a tumor response to FOLFOX/bevacizumab for colon cancer metastases in the liver
audio
Track 27 Pre- and/or postoperative adjuvant therapy for patients with resectable hepatic metastases
audio
Track 28 Neoadjuvant therapy with chemotherapy and biologics in patients with hepatic metastases
audio
Track 29 Hepatic toxicity secondary to chemotherapy
audio
Track 30 Clinical use of preoperative chemotherapy for patients with resectable liver metastases
audio
Track 31 Conversion of unresectable hepatic metastases to resectable disease with systemic therapy
audio
Track 32 Postoperative treatment decision-making based on response to neoadjuvant therapy
audio
Track 33 CAIRO2: A Phase III study of capecitabine/oxaliplatin/bevacizumab with or without cetuximab in advanced colorectal cancer
audio
Track 34 PACCE: Irinotecan/bevacizumab with or without panitumumab as first-line treatment for metastatic colorectal cancer
audio
Track 35 Potential implications of clinical trial results with combination anti-EGFR/anti-VEGF therapy in metastatic colorectal cancer
audio
Track 36 NSABP-C-08 safety data: A Phase III study of adjuvant FOLFOX6 with or without bevacizumab in the treatment of Stage II/III colon cancer
audio
Track 37 Case discussion: A 43-year-old man presenting with Stage II colon cancer and microcytic anemia
audio
Track 38 Genotyping patients with a strong family history of colorectal cancer
audio
Track 39 Development of a quantitative RT-PCR assay of 757 genes to predict risk of recurrence
audio
Track 40 Prognostic versus predictive value of multigene assays
audio
Track 41 Microsatellite instability predicts benefit from adjuvant irinotecan
audio
Track 42 Case discussion: A 45-year-old woman presenting with lactic acidosis secondary to metastatic
colon cancer
audio
Track 43 Maintenance therapy versus treatment holidays for patients with aggressively symptomatic colon cancer
audio
Track 44 Rationale for examining the genomics of the outliers in clinical research
audio
Track 45 Clinical implications of the OPTIMOX trial data for the use of treatment holidays
audio
Track 46 Capecitabine and radiation therapy as neoadjuvant treatment of rectal cancer
audio
Track 47 Postoperative treatment for patients with a complete response to neoadjuvant therapy
audio
Track 48 Potential to exclude radiation therapy for patients with rectal cancer responding to systemic therapy
audio